TOP HEADLINES

Featured Story

In Q2, diagnostics venture investment showed some signs of life

This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.

Epic Sciences' CTC cancer tests again draw Roche, Pfizer to investor table

California's Epic Sciences nailed down $30 million in new financing it plans to use to commercialize tests that can detect circulating tumor cells during a patient's treatment, allowing for a more personalized cancer treatment as the disease evolves.

Japan's Konica Minolta, New Jersey Dx outfit to develop heart attack rapid blood test

Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.

U.K. team says blood test and ultraviolet light could cheaply screen for most cancers

Even as the diagnostics industry continues to pursue more sophisticated approaches to cancer testing, a group from the U.K. has come up with a simple blood test that could generate much more bang for the buck.

Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents

Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.

MORE NEWS

From Our Sister Sites

FierceDrugDelivery

Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.

FierceBiotech

Gilead has picked up the exclusive rights to develop a set of HIV-neutralizing antibodies discovered at Theraclone in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute. Seattle-based Theraclone, which used its tech platform I-STAR in the project, picked up an unspecified set of milestones and an upfront payment in the deal.